Latest news

• Dupixent bounce-back helps stem diabetes declines at Sanofi

  Dupixent bounce-back helps stem diabetes declines at Sanofi. CEO Brandicourt says Sanofi will “enter a new growth phase”. ... A sudden uptick in sales of atopic dermatitis drug Dupixent helped offset a steep decline in diabetes sales at Sanofi in the

• Daily brief: Novartis spends big on ezcema,

  There is plenty of competition in the field, with Pfizer’s Eucrisa and Regeneron and Sanofi’s Dupixent already on the market.

• GSK sells eczema and psoriasis drug to Dermavant for £250m

  Meanwhile, in atopic dermatitis, Regeneron and Sanofi’s IL4/IL-13 inhibitor Dupixent (dupilumab) was the first biologic to be approved for the condition but seems to have stalled a little,

• Daily Brief: Airbus relocation woes, inflated taxes will pay for NHS boost, NICE OK's Sanofi's Dupixent and more

  Daily Brief: Airbus relocation woes, inflated taxes will pay for NHS boost, NICE OK's Sanofi's Dupixent and more. ... Read more from the BBC here: . NICE says yes to Sanofi’s Dupixent. England’s cost effectiveness watchdog NICE has recommended

• Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

  This year, the judges concluded that just two entrants were worthy of being shortlisted for the Innovative Product Award; Sanofi (Dupixent) and Amicus (Galafold).